OpenAI just lost one of its most powerful executives, not to a better offer or a boardroom coup, but to a chronic illness that millions of people have and that doctors spend years failing to diagnose. Fidji Simo, the company's head of product and business, announced Thursday she is stepping down after a severe worsening of Postural Orthostatic Tachycardia Syndrome, a condition she has been living with since 2019. She went on medical leave in April. She is not coming back to the role.
What POTS Actually Is, Since Most People Have No Idea
Postural Orthostatic Tachycardia Syndrome is a disorder of the autonomic nervous system. When you stand up, your heart rate spikes abnormally, your blood pressure crashes, and your body essentially forgets how to do the thing it has been doing your entire life without you thinking about it. Fatigue, brain fog, dizziness, fainting. On a bad day, getting out of bed is a genuine medical event.
It is estimated to affect somewhere between one and three million Americans, the vast majority of them women. It is also, historically, the kind of condition that gets written off as anxiety or hypochondria for years before anyone figures out what it actually is. The average time to diagnosis is over five years. Simo got her diagnosis in 2019, and she has been managing it while running product at one of the most scrutinized companies on the planet. That context matters.
Simo's Role Was Not Small
Axios reports that Simo's departure removes one of OpenAI's highest-profile executives. That is an understatement dressed up as a news hook. She came to OpenAI from Instacart, where she was CEO, and before that she spent a decade at Facebook building out some of the core product infrastructure that made the platform what it is today, for better and considerably worse.
At OpenAI, she was responsible for product and business at the exact moment the company is trying to turn an AI research lab into something that generates actual revenue and doesn't implode under its own contradictions. That is not a role you fill with a committee. Greg Brockman, OpenAI's president, stepped in to cover product during Simo's medical leave starting in April. He is still covering it now.
The Boardroom Context Here Is Not Subtle
OpenAI has had a difficult couple of years in the executive stability department, and that is the most polite possible framing. The late 2023 Sam Altman firing-and-rehiring saga alone would have broken most organizations. The company has been simultaneously converting itself from a nonprofit structure to a for-profit one, fending off Elon Musk's legal harassment campaign, and trying to ship products fast enough to stay ahead of Google, Anthropic, and a dozen other competitors who are not going to wait around.
Losing Simo right now is bad timing at an institutional level. She was reportedly a steadying presence, someone who had actually scaled consumer products before, which is a skill set that does not grow on trees in AI labs full of researchers who find deployment pipelines spiritually repugnant. The company says she will remain as a part-time advisor, which is the kind of announcement organizations make when they want to soften the blow of someone really leaving.
She Said the Quiet Part Out Loud
Simo did not issue a vague statement about pursuing new opportunities or spending time with family. She said, according to Axios, that she is stepping down because of a "severe exacerbation" of her POTS. That level of directness about a chronic illness from an executive at this level is genuinely unusual and worth pausing on.
Most executives, especially women, especially at tech companies, would sooner die than admit publicly that their body forced them out of a job. The culture around executive departures demands a fiction of choice. Simo skipped the fiction. Whether that reflects personal integrity, a desire to put a human face on a condition that desperately needs visibility, or simply the reality that her situation was too serious to spin, the effect is the same. She told the truth about why she is leaving. That is rarer than it should be.
What Happens at OpenAI Now
Greg Brockman has been holding the product chair since April. Whether OpenAI conducts an external search, promotes internally, or just lets Brockman absorb the role permanently is unclear. What is clear is that the company has a structural question to answer at exactly the moment it needs to be focused on execution.
The AI industry moves fast enough that three months of leadership uncertainty at the product level is not nothing. OpenAI is trying to be the company that wins the consumer AI race while also being the company that builds artificial general intelligence responsibly, two goals that generate friction every single day. You want steady hands at the product wheel for that. The steering committee approach has a pretty poor track record in tech.
The Dingo Take
Here is what sticks with you after reading this story. Fidji Simo ran product at one of the most powerful and controversial companies in the world while managing a chronic illness that her own nervous system was actively making worse. She did that job, by all accounts, seriously and effectively. And then her body finally said no, and she had to stop. That is the actual story. Not the org chart reshuffling. Not what this means for OpenAI's roadmap. The actual story is that a talented executive got sick enough that she had no choice but to leave a job she clearly was not done with.
POTS is not a punchline condition. It is not the kind of thing you push through with a better morning routine and adequate hydration, despite what wellness influencers who have never had a dysautonomia flare would have you believe. It is disabling in ways that are invisible from the outside, which is exactly why it gets dismissed for so long in so many patients. Simo naming it publicly, on the way out of a very high-profile job, does something real. It makes it harder for the next person with POTS to feel like they are the only one.
As for OpenAI, they will find someone to run product. They have money and leverage and desperate applicants. What they cannot manufacture is institutional knowledge built during some of the most turbulent years in the company's history. Simo had that. She is gone. The part-time advisor announcement is standard-issue face-saving language and everyone inside that building knows it. The seat is empty. Good luck filling it.
